Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Makes Hepatitis C A Priority

This article was originally published in The Pink Sheet Daily

Executive Summary

Merck highlighted its hepatitis C franchise at its recent R&D day with analysts and journalists.

Advertisement

Related Content

Collaboration With Merck’s Protease Inhibitor The Fourth HCV Tie-Up For Bristol’s Daclatasvir
A Busy Month: Russia Looks To Localization, Technology Transfer To Spur Innovation (Part 2 of 2)
Merck Talks About Its Pipeline Post-Singulair
Merck Talks About Its Pipeline Post-Singulair
Diabetes Franchise May Help Merck Offset Loss Of Singulair
Merck Looks Beyond First-In-Class Only As It Seeks To Bolster R&D Productivity
Merck Looks Beyond First-In-Class Only As It Seeks To Bolster R&D Productivity
Merck Enters The Alzheimer’s Disease Race, Plans Filings For Five New Drugs
Merck/Roche Co-Promote Pact Attempts To Shut Vertex Out Of HCV Protease Inhibitor Space
Merck To Ship Hepatitis C Drug Victrelis To Pharmacies Within A Week

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS073041

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel